Stemline Therapeutics CEO Ivan Bergstein's 2019 pay falls 44% to $5.3M
Stemline Therapeutics reports 2019 executive compensation
By ExecPay News
Published: April 29, 2020
Stemline Therapeutics reported fiscal year 2019 executive compensation information on April 29, 2020.
In 2019, four executives at Stemline Therapeutics received on average a compensation package of $2.8M, a 56% decrease compared to previous year.
Average pay of disclosed executives at Stemline Therapeutics
Ivan Bergstein, Chief Executive Officer, received $5.3M in total, which decreased by 44% compared to 2018. 64% of Bergstein's compensation, or $3.4M, was in stock awards. Bergstein also received $524K in bonus, $750K in non-equity incentive plan, as well as $647K in salary.
Kenneth Hoberman, Chief Operating Officer, received a compensation package of $2.5M, which decreased by 67% compared to previous year. 68% of the compensation package, or $1.7M, was in stock awards.
Robert Francomano, Chief Commercial Officer, earned $2.1M in 2019.
David Gionco, Chief Accounting Officer, received $1.4M in 2019, which decreases by 34% compared to 2018.
Related executives
You may also like
Source: SEC filing on April 29, 2020.